ERNA Ernexa Therapeutics Inc.
Price Chart
Executive Summary
Ernexa Therapeutics provided a business update press release highlighting progress on its lead candidate ERNA-101, including completion of process development and transition to GMP manufacturing, with an IND submission targeted for Q3 2026. No financial results were reported, and the company remains pre-revenue with a $13M market cap and a consensus EPS estimate of -$2.11 for the next quarter.
Actionable Insight
This is a pre-revenue clinical-stage biotech press release with no financial data — the stock movement will depend on investor perception of ERNA-101's probability of success. Monitor for the Q3 2026 IND submission and any partnership or financing announcements that could extend the cash runway.
Key Facts
- IND submission for ERNA-101 targeted for Q3 2026
- Process development for ERNA-101 manufacturing successfully completed
- Transition to GMP manufacturing underway
- Technology transfer activities in progress
- Company advancing toward becoming a clinical-stage biotechnology company
- Reported EPS for Q3 2023 was -$1.03 vs consensus of -$2.11 (51.2% beat), but this is a stale period
- Market cap is $13M with 0% analyst bullish rating (3 Hold, 1 Sell, 2 Strong Sell)
Financial Impact
No financial data reported; company is pre-revenue with $0 consensus revenue estimate
Risk Factors
- Pre-revenue company with no approved products — high binary risk around IND clearance and clinical trial outcomes
- Cash runway not disclosed; may require dilutive financing before reaching clinical milestones
- Weak analyst sentiment (0% bullish, 3 Hold, 1 Sell, 2 Strong Sell) and tiny market cap ($13M) suggest limited institutional support
- Historical performance shows extreme volatility: prior bullish call lost -96% at T+20, bearish call gained +96%
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301925 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
17d ago
|
Press Release
| $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $6.15 (−44.79%) |
|
May 6, 2026
5w ago
|
Press Release
| $6.04 $12.01 | ▲ +98.84% | ▲ +97.71% | $6.15 (+1.82%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $5.00 $0.2200 | ▼ −95.60% | ▼ −99.54% | $6.15 (+23.00%) |
|
Mar 24, 2026
11w ago
|
S-3/A
| $5.25 $0.2100 | ▲ +96.00% | ▲ +95.76% | $6.15 (−17.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access